MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts.

TH-302 is a hypoxia-activated prodrug known to activate selectively under the hypoxic conditions commonly found in solid tumors. It is currently being evaluated in clinical trials, including two trials in Pancreatic Ductal Adenocarcinomas (PDAC). The current study was undertaken to evaluate imaging...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Xiaomeng Zhang, Jonathan W Wojtkowiak, Gary V Martinez, Heather H Cornnell, Charles P Hart, Amanda F Baker, Robert Gillies
פורמט: Artigo
שפה:Inglês
יצא לאור: Public Library of Science (PLoS) 2016-01-01
סדרה:PLoS ONE
גישה מקוונת:http://europepmc.org/articles/PMC4882075?pdf=render
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים